Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)

被引：7

作者：

Loibl, S. ^{[1
]}

Loirat, D. ^{[2
,3
]}

Tolaney, S. M. ^{[4
]}

Punie, K. ^{[5
,6
]}

Oliveira, M. ^{[7
,8
,9
]}

Rugo, H. S. ^{[10
]}

Bardia, A. ^{[11
]}

Hurvitz, S. A. ^{[12
]}

Brufsky, A. ^{[13
,14
]}

Kalinsky, K. ^{[15
]}

Cortes, J. ^{[16
]}

O'Shaughnessy, J. ^{[17
]}

Dieras, V. C. ^{[18
]}

Carey, L. A. ^{[19
]}

Gianni, L. ^{[20
]}

Gharaibeh, M. ^{[21
]}

Moore, L. ^{[21
]}

Shi, L. ^{[22
]}

Piccart, M. ^{[23
,24
]}

机构：

[1] Hamatol Onkol Gemeinschaftspraxis Bethanien Krank, Dept Med & Res, Frankfurt, Germany

[2] Inst Curie, Med Oncol Dept, Paris, France

[3] Inst Curie, D3i, Paris, France

[4] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[5] Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium

[6] Univ Hosp Leuven, Leuven Canc Inst, Multidisciplinary Breast Ctr, Leuven, Belgium

[7] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[8] Vall dHebron Univ Hosp, Breast Canc Grp, Barcelona, Spain

[9] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[10] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[11] Harvard Med Sch, Dept Hematol & Oncol, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA

[12] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Med Oncol,Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA

[13] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Div Hematol Oncol, Pittsburgh, PA 15213 USA

[14] Univ Pittsburgh, Hillman Canc Ctr, Med Ctr, Pittsburgh, PA USA

[15] Columbia Univ Irving Med Ctr, Dept Med, New York, NY USA

[16] Quiron Grp, Med Oncol Dept, Int Breast Canc Ctr, Barcelona, Spain

[17] Texas Oncol Baylor A Charles Sammons Canc Ctr, Med Oncol, Dallas, TX USA

[18] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France

[19] Univ N Carolina, Med Hematol Oncol Div, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[20] Gianni Bonadonna Fdn, Med Oncol, Milan, Italy

[21] Gilead Sci Inc, Dept Global Value & Access, Morris Plains, NJ USA

[22] Evidera PPD, Dept Evidence Synth Modeling & Commun EMC, Waltham, MA USA

[23] Inst Jules Bordet, Med Oncol Dept, Brussels, Belgium

[24] Univ Libre Bruxelles, Brussels, Belgium

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.540

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

257P

引用

页码：S472 / S473

页数：2

共 50 条

[1] Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
Carey, Lisa A.
Zelnak, Amelia
Rugo, Hope S.
Dalenc, Florence
Nanda, Rita
Danso, Michael
Saghatchian, Mahasti
Kalinsky, Kevin
Firmin, Nelly
Ruiz-Borrego, Manuel
Favret, Anne
Sun, Jun
Schwartzberg, Lee
Hilton, Christie
Omene, Coral
Young, Robyn
Hurvitz, Sara A.
Harting, Eliza
Phan, See
Bardia, Aditya
CANCER RESEARCH, 2022, 82 (04)
[2] Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
Loibl, Sibylle
Loirat, Delphine
Tolaney, Sara M.
Punie, Kevin
Oliveira, Mafalda
Rugo, Hope S.
Bardia, Aditya
Hurvitz, Sara A.
Brufsky, Adam M.
Kalinsky, Kevin
Cortes, Javier
O'Shaughnessy, Joyce A.
Dieras, Veronique
Carey, Lisa A.
Gianni, Luca
Gharaibeh, Mahdi
Preger, Luciana
Phan, See
Chang, Lawrence
Shi, Ling
Piccart, Martine J.
EUROPEAN JOURNAL OF CANCER, 2023, 178 : 23 - 33
[3] Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
Carey, Lisa A.
Loirat, Delphine
Punie, Kevin
Bardia, Aditya
Dieras, Veronique
Dalenc, Florence
Diamond, Jennifer Robinson
Fontaine, Christel
Wang, Grace
Rugo, Hope S.
Hurvitz, Sara A.
Kalinsky, Kevin
O'Shaughnessy, Joyce
Loibl, Sibylle
Gianni, Luca
Piccart-Gebhart, Martine J.
Hong, Quan
Olivo, Martin Sebastian
Itri, Loretta
Cortes, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
Hegewisch-Becker, S.
Oliveira, M.
Traina, T.
Tolaney, S. M.
Loirat, D.
Punie, K.
Hurvitz, S. A.
Lynce, F.
Hamilton, E.
Nanda, R.
Hart, L.
Richards, P.
Malik, Z.
Rugo, H. S.
Dieras, V
Bardia, A.
Hong, Q.
Phan, S.
Itri, L. M.
Loibl, S.
Kalinsky, K.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 242 - 242
[5] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
Kalinsky, Kevin
Oliveira, Mafalda
Traina, Tiffany A.
Tolaney, Sara M.
Loirat, Delphine
Punie, Kevin
Hurvitz, Sara A.
Lynce, Filipa
Hamilton, Erika P.
Nanda, Rita
Hart, Lowell L.
Richards, Paul D.
Malik, Zulfiqar A.
Rugo, Hope S.
Dieras, Veronique
Bardia, Aditya
Hong, Quan
Olivo, Martin Sebastian
Itri, Loretta
Loibl, Sibylle
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] HEALTH UTILITIES ASSOCIATED WITH SACITUZUMAB GOVITECAN (SG) FOR TREATING UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
Benedict, A.
Rakonczai, P.
Lovato, E.
Proskorovsky, I
Xiao, Y.
Hodgson, M.
McConkey, D.
Gharaibeh, M.
VALUE IN HEALTH, 2022, 25 (12) : S82 - S82
[7] Assessment of sacituzumab govitecan (SG) in patients (pts) with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
Hegewisch-Becker, S.
Loirat, D. L.
Punie, K.
Bardia, A.
Dieras, V
Dalenc, F.
Diamond, J. R.
Fontaine, C.
Wang, G.
Rugo, H. S.
Hurvitz, S. A.
Kalinsky, K.
O'Shaughnessy, J.
Carey, L. A.
Loibl, S.
Gianni, L.
Piccart, M.
Hong, Q.
Phan, S.
Itri, L. M.
Cortes, J.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 133 - 133
[8] A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
Bardia, Aditya
Hurvitz, Sara A.
Rugo, Hope S.
Brufsky, Adam
Cortes, Javier
Loibl, Sibylle
Piccart, M.
Cowden, Janice
Spears, Patty
Carey, Lisa A.
FUTURE ONCOLOGY, 2021, 17 (30) : 3911 - 3924
[9] Metastatic triple-negative Breast Cancer (mTNBC) First-in-class Therapy with Sacituzumab Govitecan
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 64 - 65
[10] Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
Cortes, Javier
Bardia, Aditya
Loirat, Delphine
Tolaney, Sara M.
Punie, Kevin
Oliveira, Mafalda
Hurvitz, Sara A.
Brufsky, Adam
Sardesai, Sagar
Kalinsky, Kevin M.
Traina, Tiffany
Hamilton, Erika
O'Shaughnessy, Joyce
Dieras, Veronique
Carey, Lisa A.
Piccart, Martine
Loibl, Sibylle
Rugo, Hope S.
Zhu, Yanni
Phan, See
Gianni, Luca
CANCER RESEARCH, 2022, 82 (04)

← 1 2 3 4 5 →